JY
EVFM

Jeff Yass’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Jeff Yass’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-45,113
Closed -$74.4K – 14571
2022
Q1 		$230K Sell
45,113
-31,348
-41% -$197K ﹤0.01% 10916
2021
Q4 		$431K Sell
76,461
-7,573
-9% -$64.4K ﹤0.01% 9573
2021
Q3 		$931K Sell
84,034
-3,398
-4% -$42.7K ﹤0.01% 7752
2021
Q2 		$1.48M Buy
87,432
+50,210
+135% +$952K ﹤0.01% 6675
2021
Q1 		$977K Buy
37,222
+9,775
+36% +$444K ﹤0.01% 7804
2020
Q4 		$992K Sell
27,447
-736
-3% -$26.6K ﹤0.01% 6751
2020
Q3 		$998K Buy
28,183
+23,466
+497% +$1.02M ﹤0.01% 6123
2020
Q2 		$200K Buy
+4,717
New +$318K ﹤0.01% 9041
2019
Q3 		– Sell
-1,497
Closed -$149K – 11090
2019
Q2 		$149K Buy
+1,497
New +$116K ﹤0.01% 9383
2017
Q4 		– Sell
-331
Closed -$14K – 10145
2017
Q3 		$14K Buy
+331
New +$12.8K ﹤0.01% 8675

Other funds holding EVFM

CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Jeff Yass's EVFM Position: Q2 2022 in Review

Jeff Yass sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 45,113 shares — an estimated $74.4K sold.

Jeff Yass first reported a position in EVFM in Q3 2017 and held it in 10 quarters. The position peaked at $1.48M in Q2 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • Jeff Yass reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Jeff Yass sold 45,113 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $74.4K.
  • Jeff Yass first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
  • Jeff Yass's Evofem Biosciences, Inc. Common Stock position peaked at $1.48M in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.